The field of Regenerative Medicine and Bio-Pharmaceutical
Regenerative medicine is an area of medicine in which organs or tissues damaged by injury or disease are repaired by transplanting cells or tissues that restore lost functionality. Cell culture media used in regenerative medicine and biomedicine must adhere to exacting quality standards and enable safety confirmation for cultured cells. One of Shimadzu Diagnostics’s main fields of endeavor is the application of culture-medium know-how accumulated in its existing business to develop high-quality media used in regenerative medicine. Shimadzu Diagnostics provides you with high quality cell cultures and mycoplasma gene detection kit for the field of Regenerative Medicine and Bio-Pharmaceutical.
Brochure
Global Performance in the Regenerative Medicine Business
For mycoplasma testing, Nucleic Acid Amplification Technique(NAT) alone can be used as an alternative to culture method or DNA staining method.
Mycoplasma Gene Detection Kit - Myco Finder™
Solidified kit for rapidmycoplasma testingthat simplifies the complicated test operations.
Myco Finder™ leaflet
Bacteria Gene Detection Kit - BactFinder™ / Fungi Gene Detection Kit - FungiFinder™
BactFinder ™ / FungiFinder™ leaflet
Composition and usage of cell culture-related products
Cell Culture-Related Products Catalog
Custom Cell Culture Media
Contract manufacturing service
Custom Cell Culture Media leaflet
Business development in Europe
Shimadzu Diagnostics is the European subsidiary of Shimadzu Diagnostics Corporation Japan, incorporated in April 2019. NPS provides DNA extraction and PCR technologies for rapid, sensitive and cost-effective detection of mycoplasma in Advanced Therapy Medicinal Products (ATMPs) and biopharmaceuticals.
Jul 10, 2020
MycoFinder kit successfully completes EP 2.6.7 validation study
Shimadzu Diagnostics Europe has successfully completed an EP validation study in partnership with Confarma, a Solvias group company, specialized in biological analysis. MycoFinder, a mycoplasma gene detection kit, fulfils all requirements for EP 2.6.7. This Real-time PCR assay is compliant in terms of Limit of Detection (LOD), specificity and robustness. In addition, MycoFinder is comparable to compendial methods (cell culture and cell indicator methods).
MycoFinder will be available in Europe from Q3 2020.
About Solvias
Solvias is a world leader in contract analytical and process research, development and manufacturing. More information about the Solvias group can be found on the following link: https://www.solvias.com/
